The US Food and Drug Administration (FDA) has extended the review period for Soleno Therapeutics’ the New Drug Application ...

The new Prescription Drug User Fee Act (PDUFA) date for diazoxide choline extended-release (DCCR) is slated for 27 March 2025 ...

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA ...